Weiming Pharmaceutical (Stock Code: 002581) has been announced in 2023. During the reporting period, the operating income of Weiming Pharmaceutical was 209166285.01 yuan, an increase of 11.47 percent compared with 187644945.23 yuan in the same period last year.
However, the net profit attributed to shareholders of listed companies during the reporting period was-53757277.48 yuan, a decrease of 324.39% compared with 23956571.47 yuan in the same period last year. At the same time, the net profit after deducting non-recurring profits and losses belonging to shareholders of listed companies during the reporting period was-48141737.39 yuan, a decrease of 358.07% compared with 18654411.89 yuan in the same period last year. This shows that the company's profitability has declined significantly.
In terms of assets, the total assets at the end of the report were 2749586171.42 yuan, a decrease of 3.79% compared with 2857915829.17 yuan at the end of the previous year. At the end of this report, the net assets belonging to shareholders of listed companies was 2322224512.51 yuan, compared with 2373520735.73 yuan at the end of last year, a decrease of 2.16%. This reflects a reduction in the size of the company's assets and a decrease in net worth.
In terms of cash flow, the net cash flow generated by operating activities during the reporting period was-57844983.56 yuan, a decrease of 216.40% compared with-18282256.30 yuan in the same period last year. This is mainly due to the increase in expenditure on business activities in the current period. In addition, the net cash flow generated by investment activities was-24529819.32 yuan, an improvement compared with-37884412.83 yuan in the same period last year, mainly due to the decrease in expenditure on investment activities in the current period. The net cash flow generated by fund-raising activities was-17313092.56 yuan, which was significantly lower than that of 15072509.44 yuan in the same period last year, mainly due to the increase in expenditure on fund-raising activities in the current period.
According to the financial indicators, the basic earnings per share in the reporting period was-0.0815 yuan per share, a decrease of 324.52% compared with 0.0363 yuan per share in the same period last year. Diluted earnings per share is also-0.0815 yuan per share, consistent with basic earnings per share. The weighted average return on net assets during the reporting period was-2.31%, down 3.31% from 1.00% in the same period last year. The changes in these indicators further reflect the decline in the company's profitability.
Generally speaking, Weiming Pharmaceutical showed the growth of operating income in 2023, but the net profit decreased significantly, the cash flow pressure appeared and the profitability decreased. As a financial analyst, I think investors should fully take these risk factors into account when considering investing in unknown medicine. In the future, Weiming Pharmaceutical needs to improve its financial situation and enhance the confidence of investors by improving operating efficiency, optimizing asset structure, improving profitability and other ways.
This article only represents the judgment made by the analyst himself or the analyst on the basis of AI analysis, and can not be used as any investment index, nor does it constitute any investment advice. The original intention of this paper is to help investors analyze and judge the capital market data in the most intuitive and fast way and from the most professional perspective.